Company intelligence / Profile preview

Veratrum

South San Francisco, California, United Statesx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Atacicept has demonstrated potential to stabilize kidney function, reduce proteinuria, and improve hematuria in patients with IgAN through pivotal Phase 2b and ongoing Phase 3 trials. The company also develops MAU868 targeting BK virus.

Therapeutic areas: ImmunologyNephrologyInfectious Diseases
Modalities: Recombinant fusion proteins (e.g., atacicept)Monoclonal antibodies (e.g., MAU868)
Industry: Biotech

Drug pipeline

2 assets

DY131

Pre-clinical

Indications: Basal cell carcinoma, Medulloblastoma

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Veratrum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veratrum.

Explore the full profile